Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia, Myelodysplastic syndrome (MDS)
Results
Phase 2
This study looked at lenalidomide (Revlimid) on its own and in combination with chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome in people who had changes to a particular chromosome (a ‘chromosomal abnormality’).
This trial was supported by Cancer Research UK.
Recruitment start: 20 August 2009
Recruitment end: 18 May 2010
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David Bowen
Cancer Research UK
Celgene
Experimental Cancer Medicine Centre (ECMC)
Leeds Institute of Clinical Trials Research (University of Leeds)
Leeds Teaching Hospitals NHS Trust
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/08/026.
Last reviewed: 7 January 2014
CRUK internal database number: 3489
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
